Items Tagged ‘odomzo’

August 13th, 2015

Food and Drug Administration approves Odomzo for treatment of basal cell carcinoma


The U. S. Food and Drug Administration approved Odomzo® (sonidegib, formerly LDE225) for the treatment of patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. The approval was based on demonstration of a durable objective response rate […]

View full entry

Tags: basal cell carcinoma, General Skin Cancer, News, odomzo, Skin Cancer